Editorial
ABSTRACT
For access to the full length article, please sign in.
Immuno-Oncology Essentials: An Overview
Brianna Hoffner, MSN, ANP-BC, AOCNP®
University of Colorado Cancer Center—Anschutz, Aurora, Colorado
Author’s disclosures of conflicts of interest are found at the end of this article.
Brianna Hoffner, MSN, ANP-BC, AOCNP®, 1665 Aurora Court, Aurora, CO 80045. E-mail: brianna.hoffner@ucdenver.edu
J Adv Pract Oncol 2019;10(suppl 1):7–8 | https://doi.org/10.6004/jadpro.2019.10.2.9 | © 2019 Harborside™
University of Colorado Cancer Center—Anschutz, Aurora, Colorado
Author’s disclosures of conflicts of interest are found at the end of this article.
Brianna Hoffner, MSN, ANP-BC, AOCNP®, 1665 Aurora Court, Aurora, CO 80045. E-mail: brianna.hoffner@ucdenver.edu
J Adv Pract Oncol 2019;10(suppl 1):7–8 | https://doi.org/10.6004/jadpro.2019.10.2.9 | © 2019 Harborside™
ABSTRACT
This article is a part of a JADPRO certified supplement, Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
Table of Contents
- Immuno-Oncology Essentials: An Overview (current article)
- Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care
- PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
- Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
- Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types
- Appendix: Care Step Pathway Tools for Immune-Related Adverse Event Assessment and Management
For access to the full length article, please sign in.